Safety and Efficacy of DA-9805 for Parkinson's Disease

Summary

This is a phase IIa, first in human, randomized, double-blind, multicenter study to evaluate the safety, tolerability and efficacy of DA-9805 at 45mg, 90mg versus placebo in subjects diagnosed with early Parkinson's disease.

Timeline

Start

2018-02-06

Primary completion

2019-04-10

Completion

2019-04-10

Outcome

Missed primary endpoint

registry Placebo vs DA-9805 Low; p = 0.3656 NCT03189563 ↗

registry Placebo vs DA-9805 High; p = 0.3119 NCT03189563 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DA-9805	Traditional medicine (herbal / TCM)	15 mg	—
Subject	DA-9805	Traditional medicine (herbal / TCM)	30 mg	—

Indications